These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 22296623)

  • 1. Ritonavir interacts with bortezomib to enhance protein ubiquitination and histone acetylation synergistically in renal cancer cells.
    Sato A; Asano T; Ito K; Asano T
    Urology; 2012 Apr; 79(4):966.e13-21. PubMed ID: 22296623
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Suberoylanilide hydroxamic acid (SAHA) combined with bortezomib inhibits renal cancer growth by enhancing histone acetylation and protein ubiquitination synergistically.
    Sato A; Asano T; Ito K; Sumitomo M; Asano T
    BJU Int; 2012 Apr; 109(8):1258-68. PubMed ID: 21895936
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vorinostat and bortezomib synergistically cause ubiquitinated protein accumulation in prostate cancer cells.
    Sato A; Asano T; Ito K; Asano T
    J Urol; 2012 Dec; 188(6):2410-8. PubMed ID: 23088964
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Panobinostat synergizes with bortezomib to induce endoplasmic reticulum stress and ubiquitinated protein accumulation in renal cancer cells.
    Sato A; Asano T; Isono M; Ito K; Asano T
    BMC Urol; 2014 Aug; 14():71. PubMed ID: 25176354
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells.
    Nawrocki ST; Carew JS; Pino MS; Highshaw RA; Andtbacka RH; Dunner K; Pal A; Bornmann WG; Chiao PJ; Huang P; Xiong H; Abbruzzese JL; McConkey DJ
    Cancer Res; 2006 Apr; 66(7):3773-81. PubMed ID: 16585204
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination of suberoylanilide hydroxamic acid and ritonavir is effective against renal cancer cells.
    Sato A; Asano T; Horiguchi A; Ito K; Sumitomo M; Asano T
    Urology; 2010 Sep; 76(3):764.e7-13. PubMed ID: 20630573
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interactions between bortezomib and romidepsin and belinostat in chronic lymphocytic leukemia cells.
    Dai Y; Chen S; Kramer LB; Funk VL; Dent P; Grant S
    Clin Cancer Res; 2008 Jan; 14(2):549-58. PubMed ID: 18223231
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.
    Pei XY; Dai Y; Grant S
    Clin Cancer Res; 2004 Jun; 10(11):3839-52. PubMed ID: 15173093
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Romidepsin induces cell cycle arrest, apoptosis, histone hyperacetylation and reduces matrix metalloproteinases 2 and 9 expression in bortezomib sensitized non-small cell lung cancer cells.
    Karthik S; Sankar R; Varunkumar K; Ravikumar V
    Biomed Pharmacother; 2014 Apr; 68(3):327-34. PubMed ID: 24485799
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The proteasome inhibitor bortezomib interacts synergistically with the histone deacetylase inhibitor suberoylanilide hydroxamic acid to induce T-leukemia/lymphoma cells apoptosis.
    Zhang QL; Wang L; Zhang YW; Jiang XX; Yang F; Wu WL; Janin A; Chen Z; Shen ZX; Chen SJ; Zhao WL
    Leukemia; 2009 Aug; 23(8):1507-14. PubMed ID: 19282831
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ritonavir induces endoplasmic reticulum stress and sensitizes sarcoma cells toward bortezomib-induced apoptosis.
    Kraus M; Malenke E; Gogel J; Müller H; Rückrich T; Overkleeft H; Ovaa H; Koscielniak E; Hartmann JT; Driessen C
    Mol Cancer Ther; 2008 Jul; 7(7):1940-8. PubMed ID: 18645004
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of noncompetitive proteasome inhibition on bortezomib resistance.
    Li X; Wood TE; Sprangers R; Jansen G; Franke NE; Mao X; Wang X; Zhang Y; Verbrugge SE; Adomat H; Li ZH; Trudel S; Chen C; Religa TL; Jamal N; Messner H; Cloos J; Rose DR; Navon A; Guns E; Batey RA; Kay LE; Schimmer AD
    J Natl Cancer Inst; 2010 Jul; 102(14):1069-82. PubMed ID: 20505154
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aggravated endoplasmic reticulum stress as a basis for enhanced glioblastoma cell killing by bortezomib in combination with celecoxib or its non-coxib analogue, 2,5-dimethyl-celecoxib.
    Kardosh A; Golden EB; Pyrko P; Uddin J; Hofman FM; Chen TC; Louie SG; Petasis NA; Schönthal AH
    Cancer Res; 2008 Feb; 68(3):843-51. PubMed ID: 18245486
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Delanzomib Interacts with Ritonavir Synergistically to Cause Endoplasmic Reticulum Stress in Renal Cancer Cells.
    Isono M; Sato A; Asano T; Okubo K; Asano T
    Anticancer Res; 2018 Jun; 38(6):3493-3500. PubMed ID: 29848702
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Dual Histone Deacetylase-Proteasome Inhibitor RTS-V5 Acts Synergistically With Ritonavir to Induce Endoplasmic Reticulum Stress in Bladder Cancer Cells.
    Okubo K; REßING N; Schulz WA; Hansen FK; Asano T; Sato A
    Anticancer Res; 2021 Dec; 41(12):5987-5996. PubMed ID: 34848452
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The combined therapeutic effects of bortezomib and fenretinide on neuroblastoma cells involve endoplasmic reticulum stress response.
    Pagnan G; Di Paolo D; Carosio R; Pastorino F; Marimpietri D; Brignole C; Pezzolo A; Loi M; Galietta LJ; Piccardi F; Cilli M; Nico B; Ribatti D; Pistoia V; Ponzoni M
    Clin Cancer Res; 2009 Feb; 15(4):1199-209. PubMed ID: 19228726
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma.
    Heider U; von Metzler I; Kaiser M; Rosche M; Sterz J; Rötzer S; Rademacher J; Jakob C; Fleissner C; Kuckelkorn U; Kloetzel PM; Sezer O
    Eur J Haematol; 2008 Feb; 80(2):133-42. PubMed ID: 18005386
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HDAC inhibitor L-carnitine and proteasome inhibitor bortezomib synergistically exert anti-tumor activity in vitro and in vivo.
    Huang H; Liu N; Yang C; Liao S; Guo H; Zhao K; Li X; Liu S; Guan L; Liu C; Xu L; Zhang C; Song W; Li B; Tang P; Dou QP; Liu J
    PLoS One; 2012; 7(12):e52576. PubMed ID: 23285100
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in cutaneous T cell lymphoma.
    Heider U; Rademacher J; Lamottke B; Mieth M; Moebs M; von Metzler I; Assaf C; Sezer O
    Eur J Haematol; 2009 Jun; 82(6):440-9. PubMed ID: 19220424
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumor effect of the human immunodeficiency virus protease inhibitor ritonavir: induction of tumor-cell apoptosis associated with perturbation of proteasomal proteolysis.
    Gaedicke S; Firat-Geier E; Constantiniu O; Lucchiari-Hartz M; Freudenberg M; Galanos C; Niedermann G
    Cancer Res; 2002 Dec; 62(23):6901-8. PubMed ID: 12460905
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.